Reprieve Cardiovascular Announces Publication of FASTR Pilot Trial Results in JACC: Heart Failure
— Peer-reviewed publication reports faster decongestion with Reprieve Therapy and no increased risk of safety events or worsening kidney function compared to optimal diuretic therapy — MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced the publication of results from its FASTR randomized pilot study … [Read more…]
